The University of Alabama at Birmingham Department of Obstetrics and Gynecology has enrolled the first patient in the United States in a Phase III clinical trial for a drug to treat preeclampsia in pregnant women that, if successful, would be a significant clinical breakthrough for reducing pre-term births and infant mortality.
“Currently, when patients have preeclampsia, all we have to offer is delivery of the baby as the ultimate treatment,” said Alan Tita, M.D., Ph.D., professor of Obstetrics and Gynecology in UAB’s School of Medicine and a lead investigator for the trial.
Click on the link below to read the full article.
http://www.uab.edu/news/innovation/item/4993-uab-enrolls-nation-s-first-patient-in-phase-iii-drug-trial-for-preeclampsia
